AnaBios is pleased to announce that Stanford University researchers David Yeomans, PhD, and Justin Meyerowitz, MD, PhD, are the winners of our first annual Translational Research Grant Award. The Stanford researchers will obtain up to $15,000 in AnaBios high-quality human tissue samples to be used for their project determining the translatability of oxytocin efficacy in human cells compared to data from rodent models.
Dr. Yeomans is the Director of Pain Research and Faculty of Anesthesia at Stanford University. His lab primarily focuses on distinguishing the science underlying different types of pain, identifying markers of the different pain types, and developing novel therapeutics targeting these distinct pain types. He is heavily involved in teaching, directing the Neuroscience Scholarly Concentration for medical students, as well as a didactic course for these students. He is author of more than 130 papers and 11 book chapters on the subject of pain, as well as being an inventor on 10 US patents and applications, consults for numerous pharmaceutical, device, investment, and law firms, and has founded two privately-funded biotechnology concerns. Yeomans earned his AB in Psychology from Dartmouth College and PhD in Neuroscience from the University of Florida and completed a postdoctoral fellowship in Pharmacology at the University of Illinois.
Dr. Meyerowitz is an Anesthesiologist and Research Fellow in the Departments of Anesthesiology and Molecular and Cellular Physiology at Stanford University. In the laboratory of Georgios Skiniotis, his research leverages new tools in structural biology and biochemistry to advance understanding of G protein-coupled receptor pharmacology and drug discovery, with an emphasis on the oxytocin/vasopressin receptor system. Previously, Meyerowitz was a resident in Anesthesiology and intern in Internal Medicine at Stanford. He obtained his MD from University of California-San Franciso and PhD in Chemistry and Chemical Biology in the laboratories of Bill Weiss and Kevan Shokat, where he used a structure-based approach to design small molecules targeting a previously undruggable protein-protein interaction.
The top 10 entries into the translational research competition received a 25% discount from AnaBios towards human tissue samples for their respective research projects.